Sanofi Under Pressure: Shares Drop 2.32% to Close at 80.50 Euros
Sanofi's stock closed down 2.32% at 80.50 euros this Tuesday, January 13, touching its support threshold at 80.60 euros. This challenging session comes as the European Commission has just approved Teizeild to delay stage 3 type 1 diabetes.
Market Performance and Technical Indicators
Sanofi's shares closed at 80.50 euros this Tuesday, January 13, marking a decrease of 2.32% from the previous closing price of 82.41 euros. The stock is now hovering just above its support threshold at 80.60 euros, a key area that may be tested in upcoming sessions. The Relative Strength Index (RSI) is at 51, in a neutral zone indicating neither overbought nor oversold conditions, yet it reflects a lack of strong upward momentum following the technical rebound observed on January 9. The gap with the 50-day moving average, which stands at 84.81 euros, has widened, highlighting the stock's deviation from its medium-term equilibrium. Over the past week, the stock has declined by 0.85%, partially erasing the gains made at the end of last week. The stock remains significantly down over the year with a loss of 15.8%, confirming a still challenging sector context for large pharmaceutical companies. Breaking below the support threshold could lead to a new phase of technical consolidation, with an increased risk of sliding towards recent lows.
Regulatory Advances and Strategic Developments
The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes in adult patients and children, as announced on January 12, 2026. This approval marks a new milestone in the group's strategy to strengthen its immunology portfolio. In January, Sanofi also submitted a request to extend the indication of Tzield to children as young as one year, with an FDA priority review expected in April 2026. These regulatory advancements come as the company increases its investments in R&D and targeted acquisitions, such as the purchase of Dynavax Technologies for $2.2 billion completed in December 2025. Despite these positive strategic announcements, the market appears to remain cautious for the time being. The stock continues to face pressure from a challenging stock market environment and a valuation still deemed cautious by some analysts. However, bank recommendations remain predominantly favorable: Grupo Santander maintains a price target of 106 euros with an outperformance rating, while Berenberg has a target of 105 euros with a buy rating, representing potential upsides of 24 to 31% from the current price.
